Metformina Accordpharma

Metformin, the active ingredient in Metformina Accordpharma, is a biguanide presented as a unknown/unknown for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑sugar control. GNH USA supplies Metformina Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Accordpharma is indicated for conditions within the glucose‑regulation pathway. - Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes: helps delay progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome (PCOS): reduces insulin resistance and may improve menstrual regularity.

Metformina Accordpharma may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: when combined with insulin or secretagogues. - Anemia: due to folate deficiency. - Electrolyte imbalance: especially with prolonged diarrhea.

Metformina Accordpharma requires careful monitoring in several clinical situations. - Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: use cautiously in patients with liver disease. - Blood glucose monitoring: adjust therapy based on glycemic response. - Elderly patients: start at lower dose and titrate slowly. - Heart failure: evaluate risk of lactic acidosis in unstable patients. - Store at below 25°C: keep in the original pack, protect from moisture.

Metformina Accordpharma can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of acute kidney injury and lactic acidosis. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium. - Calcium channel blockers: may modestly increase metformin levels. - Oral contraceptives: may slightly raise plasma metformin concentrations.